(2R,3aR,9aR)-2-(6-Chloro-purin-9-yl)-5,5,7,7-tetraisopropyl-dihydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-3-one | 129932-37-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (2R,3aR,9aR)-2-(6-Chloro-purin-9-yl)-5,5,7,7-tetraisopropyl-dihydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-3-one
• 英文别名: (6aR,8R,9aR)-8-(6-chloropurin-9-yl)-2,2,4,4-tetra(propan-2-yl)-6a,9a-dihydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-one
• CAS: 129932-37-2
• 化学式: C₂₂H₃₅ClN₄O₅Si₂
• 分子量: 527.168
• InChiKey: LWSAVMQIMJUMPF-ZWDAVXSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  34.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  97.59
• 氢给体数：
  0.0
• 氢受体数：
  9.0

反应信息

• 作为反应物：
  描述：

  (2R,3aR,9aR)-2-(6-Chloro-purin-9-yl)-5,5,7,7-tetraisopropyl-dihydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-3-one 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.33h， 生成 9-[(6aR,9aS)-2,2,4,4-tetra(propan-2-yl)-6a,9a-dihydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-6-chloro-8-(2,2-dibromoethenyl)purine
  参考文献：
  名称：

  Radical-Mediated Cyclization of A 6-Chloro-9-(2-Deoxy--derythro-pent-1-enofuranosyl)-8-(2,2-dibromovinyl) purine

  摘要：

  A vinyl radical generated from a 6-chloro-9-(2-deoxy-D-erythro-pent-1-eno-furanosyl)-8- (2,2-dibromovinyl)purine effected cyclization either at the 1'- or at the 2'-position. The result is discussed in comparison with our previous study of the corresponding uracil derivative.

  DOI：

  10.1080/07328319608002446
• 作为产物：
  描述：

  1,3二氯-1,1,3,3-四异丙基二硅氧烷 在 吡啶 作用下， 以 乙腈 为溶剂， 反应 9.0h， 生成 (2R,3aR,9aR)-2-(6-Chloro-purin-9-yl)-5,5,7,7-tetraisopropyl-dihydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-3-one
  参考文献：
  名称：

  [EN] NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY
  [FR] COMPOSÉS NUCLÉOSIDE-THIODIPHOSPHATE-HEPTOSE POUR TRAITER DES AFFECTIONS ASSOCIÉES À L'ACTIVITÉ DE L'ALPK1

  摘要：

  本发明涉及式(I)的化合物，该化合物调节，特别是激活α激酶1(ALPK1)，并且适用于治疗某种疾病、病症或障碍，其中ALPK1活性的降低或增加会导致该疾病、病症或障碍的病理学、症状或进展，例如癌症、免疫或炎症相关疾病。

  公开号：

  WO2022127914A1

文献信息

• Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication
  作者：Jeremy L. Clark、J. Christian Mason、Laurent Hollecker、Lieven J. Stuyver、Phillip M. Tharnish、Tamara R. McBrayer、Michael J. Otto、Phillip A. Furman、Raymond F. Schinazi、Kyoichi A. Watanabe

  DOI：10.1016/j.bmcl.2005.12.002

  日期：2006.3

  A series of purine nucleosides containing the 2'-deoxy-2'-fluoro-2'-C-methylribofuranosyl moiety were synthesized and evaluated as potential inhibitors of the hepatitis C virus in vitro. Of the nucleosides that were synthesized, only those possessing a 2-amino group on the purine base reduced the levels of HCV RNA in a subgenomic replicon assay.

  合成了一系列含有2'-脱氧-2'-氟-2'-C-甲基呋喃呋喃糖基部分的嘌呤核苷，并作为体外丙型肝炎病毒的潜在抑制剂进行了评估。在合成的核苷中，只有在嘌呤碱基上具有2-氨基的核苷才能在亚基因组复制子测定中降低HCV RNA的水平。
• Synthesis of 2'-C-Difluoromethyl Substituted Nucleoside Analogs as Ribonucleoside Replacements in Hammerhead Ribozymes
  作者：Martin Dunkel、Vivian Reither、Susanne Ebel-Will、János Ludwig

  DOI：10.1080/15257779508012474

  日期：1995.5.1

  2'-Difluoromethyl modified nucleoside analogs 4 and 9 have been prepared and converted into phosphoramidites for the incorporation into hammerhead ribozymes.
• A Convenient Route to 2′-Allenyl Nucleosides
  作者：Esa T. Jarvi、James R. McCarthy

  DOI：10.1080/15257779408013264

  日期：1994.3

  The first synthesis of allenic nucleosides derived from natural ribonucleosides is reported. 2'-Deoxy-2'-(ethenylidene)cytidine (8) and 2'-deoxy-2'-(ethenylidine)adenosine (21) were prepared by a modification of the method developed by Tsuji and co-workers for the synthesis of allenes. The biological rationale for the synthesis of these compounds is discussed.
• MCCARTHY, JAMES R.;MATTHEWS, DONALD P.;EDWARDS, MICHAEL L.;STEMERICK, DAV+, TETRAHEDRON LETT., 31,(1990) N8, C. 5449-5452
  作者：MCCARTHY, JAMES R.、MATTHEWS, DONALD P.、EDWARDS, MICHAEL L.、STEMERICK, DAV+

  DOI：——

  日期：——